tbuckley/cabot-search huggingface dataset:
Esophageal Manometry and Regional Transpulmonary Pressure in Lung Injury
Authors: Takeshi Yoshida, Marcelo B. P. Amato, Domenico Luca Grieco, Lu Chen, Cristhiano A. S. Lima, Rollin Roldan, Caio C. A. Morais, Susimeire Gomes, Eduardo L. V. Costa, Paulo F. G. Cardoso, Emmanuel Charbonney, Jean-Christophe M. Richard, Laurent Brochard, Brian P. Kavanagh
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Rationale: Esophageal manometry is the clinically available method to estimate pleural pressure, thus enabling calculation of transpulmonary pressure (Pl). However, many concerns make it uncertain in which lung region esophageal manometry reflects local Pl.Objectives: To determine the accuracy of esophageal pressure (Pes) and in which regions esophageal manometry reflects pleural pressure (Ppl) and Pl; to assess whether lung stress in nondependent regions can be estimated at end-inspiration from Pl.Methods: In lung-injured pigs (n = 6) and human cadavers (n = 3), Pes was measured across a range of positive end-expiratory pressure, together with directly measured Ppl in nondependent and dependent pleural regions. All measurements were obtained with minimal nonstressed volumes in the pleural sensors and esophageal balloons. Expiratory and inspiratory Pl was calculated by subtracting local Ppl or Pes from airway pressure; inspiratory Pl was also estimated by subtracting Ppl (calculated from chest wall and respiratory system elastance) from the airway plateau pressure.Measurements and Main Results: In pigs and human cadavers, expiratory and inspiratory Pl using Pes closely reflected values in dependent to middle lung (adjacent to the esophagus). Inspiratory Pl estimated from elastance ratio reflected the directly measured nondependent values.Conclusions: These data support the use of esophageal manometry in acute respiratory distress syndrome. Assuming correct calibration, expiratory Pl derived from Pes reflects Pl in dependent to middle lung, where atelectasis usually predominates; inspiratory Pl estimated from elastance ratio may indicate the highest level of lung stress in nondependent “baby” lung, where it is vulnerable to ventilator-induced lung injury.
Identification of a Compound Overcoming Drug Resistance of Myeloma Cells at Hypoxic Condition
Authors: Eri Fujii, Yuki Inada, Misaki Kakoki, Nao Nishimura, Shinya Endo, Shiho Fujiwara, Naoko Wada, Yawara Kawano, Yutaka Okuno, Toshiya Sugimoto, Hiroyuki Hata
Journal: Blood (2017)
Review: In adults, contrast-enhanced CT is not linked to acute kidney injury or mortality vs noncontrast CT
Authors: Tejas Patel, Vihas Patel
Journal: Annals of Internal Medicine (2018)

ACP Journal Club16 January 2018Review: In adults, contrast-enhanced CT is not linked to acute kidney injury or mortality vs noncontrast CTTejas Patel, MD, FASN, Vihas Patel, MDTejas Patel, MD, FASNIcahn School of Medicine at Mount Sinai, New York City, New York, USA (T.P.)Search for more papers by this author, Vihas Patel, MDZucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York, USA (V.P.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2018-168-2-010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationAycock RD, Westafer LM, Boxen JL, et al. Acute kidney injury after computed tomography: a meta-analysis. Ann Emerg Med. 2017 Aug 12. [Epub ahead of print]. https://pubmed.ncbi.nlm.nih.gov/28811122Clinical Impact RatingsEmergency Med: Hospitalists: Nephrology: References1 McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016;68:1465-73. [PMID: 27659469] Google Scholar2 Canadian Association of Radiologists. Consensus guidelines for the prevention of contrast induced nephropathy. www.car.ca/uploads/standards%20guidelines/20110617_en_prevention_cin.pdf (accessed 7 Nov 2017). Google Scholar3 Mehran risk score calculator. www.zunis.org/Contrast-Induced%20Nephropathy%20Calculator.htm (accessed 7 Nov 2017). Google Scholar4 Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012:2:1-138. Google Scholar Author, Article, and Disclosure InformationAffiliations: Icahn School of Medicine at Mount Sinai, New York City, New York, USA (T.P.)Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York, USA (V.P.)This article was published at Annals.org on 2 January 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 16 January 2018Volume 168, Issue 2Page: JC10KeywordsAcute kidney injuryAcute renal failureCervical intraepithelial neoplasiaComputed axial tomographyMortalityObservational studiesOdds ratioRandomized trialsRetrospective studiesStatins ePublished: 16 January 2018 Issue Published: 16 January 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Rain (Renal AL Amyloid Involvement And NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic AL Amyloidosis and Persistent Renal Involvement
Authors: Cindy Varga, Angela Dispenzieri, Morie A. Gertz, Stacey A Goodman, Kristen Hsu, Leslie Inker, Heather Landau, Nelson Leung, Joseph R. Mikhael, Taimur Sher, Brendan M Weiss, Sandy W. Wong, Jeffrey A Zonder, Raymond L. Comenzo
Journal: Blood (2017)
Comparison Between ImmunoCAP And RAST For Diagnosis Of Hypersensitivity To Betalactams
Authors: Inmaculada Doña, Natalia Pérez-Sánchez, Esther Barrionuevo, Ruben Fernandez, Maria Isabel Montañez, Maria Isabel Sanchez, Ana Molina, Cristobalina Mayorga, Maria Jose Torres Jaén
Journal: Journal of Allergy and Clinical Immunology (2018)
Epidemiology of atopic dermatitis in adults: Results from an international survey
Authors: S. Barbarot, S. Auziere, A. Gadkari, G. Girolomoni, L. Puig, E. L. Simpson, D. J. Margolis, M. de Bruin‐Weller, L. Eckert
Journal: Allergy (2018)

Abstract Background There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). Objective To estimate the prevalence of AD in adults and by disease severity. Methods This international, cross‐sectional, web‐based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United Kingdom, and Japan. Adult members of online respondent panels were sent a questionnaire for AD identification and severity assessment; demographic quotas ensured population representativeness for each country. A diagnosis of AD required subjects to be positive on the modified UK Working Party/ISAAC criteria and self‐report of ever having an AD diagnosis by a physician. The proportion of subjects with AD who reported being treated for their condition was determined and also used to estimate prevalence. Severity scales were Patient‐Oriented SCORAD, Patient‐Orientated Eczema Measure, and Patient Global Assessment. Results Among participants by region, the point prevalence of adult AD in the overall/treated populations was 4.9%/3.9% in the US, 3.5%/2.6% in Canada, 4.4%/3.5% in the EU, and 2.1%/1.5% in Japan. The prevalence was generally lower for males vs females, and decreased with age. Regional variability was observed within countries. Severity varied by scale and region; however, regardless of the scale or region, proportion of subjects reporting severe disease was lower than mild or moderate disease. Conclusions Prevalence of adult AD ranged from 2.1% to 4.9% across countries. Severe AD represented a small proportion of the overall AD population regardless of measure or region.
APE1- and APE2-dependent DNA breaks in immunoglobulin class switch recombination
Authors: Jeroen E.J. Guikema, Erin K. Linehan, Daisuke Tsuchimoto, Yusaku Nakabeppu, Phyllis R. Strauss, Janet Stavnezer, Carol E. Schrader
Journal: The Journal of Experimental Medicine (2007)
KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop
Authors: Ken Fujimura, Huawei Wang, Felicia Watson, Richard L. Klemke
Journal: Cancer Research (2018)

Abstract There remains intense interest in tractable approaches to target or silence the KRAS oncoprotein as a rational therapeutic strategy to attack pancreatic ductal adenocarcinoma (PDAC) and other cancers that overexpress it. Here we provide evidence that accumulation of the KRAS oncoprotein is controlled by a self-regulating feed-forward regulatory loop that utilizes a unique hypusinated isoform of the translation elongation factor eIF5A and the tyrosine kinase PEAK1. Oncogenic activation of KRAS increased eIF5A–PEAK1 translational signaling, which in turn facilitated increased KRAS protein synthesis. Mechanistic investigations show that this feed-forward positive regulatory pathway was controlled by oncogenic KRAS-driven metabolic demands, operated independently of canonical mTOR signaling, and did not involve new KRAS gene transcription. Perturbing eIF5A–PEAK1 signaling, by genetic or pharmacologic strategies or by blocking glutamine synthesis, was sufficient to inhibit expression of KRAS, eIF5A, and PEAK1, to attenuate cancer cell growth and migration, and to block tumor formation in established preclinical mouse models of PDAC. Levels of KRAS, eIF5A, and PEAK1 protein increased during cancer progression with the highest levels of expression observed in metastatic cell populations. Combinatorial targeting of eIF5A hypusination and the RAS–ERK signaling pathway cooperated to attenuate KRAS expression and its downstream signaling along with cell growth in vitro and tumor formation in vivo. Collectively, our findings highlight a new mechanistic strategy to attenuate KRAS expression as a therapeutic strategy to target PDAC and other human cancers driven by KRAS activation. Significance: These findings highlight a new mechanistic strategy to attenuate KRAS expression as a therapeutic strategy to target human cancers driven by KRAS activation. Cancer Res; 78(6); 1444–56. ©2018 AACR.
Ambient carbon monoxide and cardiovascular mortality: a nationwide time-series analysis in 272 cities in China
Authors: Cong Liu, Peng Yin, Renjie Chen, Xia Meng, Lijun Wang, Yue Niu, Zhijing Lin, Yunning Liu, Jiangmei Liu, Jinlei Qi, Jinling You, Haidong Kan, Maigeng Zhou
Journal: The Lancet Planetary Health (2018)

BackgroundEvidence of the acute health effects of ambient carbon monoxide air pollution in developing countries is scarce and mixed. We aimed to evaluate short-term associations between carbon monoxide and daily cardiovascular disease mortality in China.MethodsWe did a nationwide time-series analysis in 272 major cities in China from January, 2013, to December, 2015. We extracted daily cardiovascular disease mortality data from China's Disease Surveillance Points system. Data on daily carbon monoxide concentrations for each city were obtained from the National Urban Air Quality Real-time Publishing Platform. City-specific associations between carbon monoxide concentrations and daily mortality from cardiovascular disease, coronary heart disease, and stroke were estimated with over-dispersed generalised linear models. Bayesian hierarchical models were used to obtain national and regional average associations. Exposure–response association curves and potential effect modifiers were evaluated. Two-pollutant models were fit to evaluate the robustness of the effects of carbon monoxide on cardiovascular mortality.FindingsThe average annual mean carbon monoxide concentration in these cities from 2013 to 2015 was 1·20 mg/m3, ranging from 0·43 mg/m3 to 2·45 mg/m3. For a 1 mg/m3 increase in average carbon monoxide concentrations on the present day and previous day (lag 0–1), we observed significant increments in mortality of 1·12% (95% posterior interval [PI] 0·42–1·83) from cardiovascular disease, 1·75% (0·85–2·66) from coronary heart disease, and 0·88% (0·07–1·69) from stroke. These associations did not vary substantially by city, region, and demographic characteristics (age, sex, and level of education), and the associations for cardiovascular disease and coronary heart disease were robust to the adjustment of criteria co-pollutants. We did not find a threshold below which carbon monoxide exposure had no effect on cardiovascular disease mortality.InterpretationThis analysis is, to our knowledge, the largest study done in a developing country, and provides robust evidence of the association between short-term exposure to ambient carbon monoxide and increased cardiovascular disease mortality, especially coronary heart disease mortality.FundingPublic Welfare Research Program.
Comparison of symptoms during a conjunctival provocation test (CPT) and a controlled exposure to birch pollen in the Strasbourg Environmental Exposure Chamber (EEC) ( ALYATEC)
Authors: Ibrahim Choual, Carmen Radu, Naji Khayath, Nicole Beck, Florian Schoettel, Audrey Jacob, Nathalie Domis, Frederic J. de Blay
Journal: Journal of Allergy and Clinical Immunology (2018)
Perturbations of gut microbiome genes in infants with atopic dermatitis according to feeding type
Authors: Min-Jung Lee, Mi-Jin Kang, So-Yeon Lee, Eun Lee, Kangjin Kim, Sungho Won, Dong In Suh, Kyung Won Kim, Youn Ho Sheen, Kangmo Ahn, Bong-Soo Kim, Soo-Jong Hong
Journal: Journal of Allergy and Clinical Immunology (2018)
Physical Properties of Implanted Porous Bioscaffolds Regulate Skin Repair: Focusing on Mechanical and Structural Features
Authors: Shumeng Jiang, Sabrina Cloud Li, Chenyu Huang, Barbara Pui Chan, Yanan Du
Journal: Advanced Healthcare Materials (2018)

Abstract Porous bioscaffolds are applied to facilitate skin repair since the early 1990s, but a perfect regeneration outcome has yet to be achieved. Until now, most efforts have focused on modulating the chemical properties of bioscaffolds, while physical properties are traditionally overlooked. Recent advances in mechanobiology and mechanotherapy have highlighted the importance of biomaterials' physical properties in the regulation of cellular behaviors and regenerative processes. In skin repair, the mechanical and structural features of porous bioscaffolds are two major physical properties that determine therapeutic efficacy. Here, first an overview of natural skin repair with an emphasis on the major biophysically sensitive cell types involved in this multistage process is provided, followed by an introduction of the four roles of bioscaffolds as skin implants. Then, how the mechanical and structural features of bioscaffolds influence these four roles is discussed. The mechanical and structural features of porous bioscaffolds should be tailored to balance the acceleration of wound closure and functional improvements of the repaired skin. This study emphasizes that decoupling and precise control of the mechanical and structural features of bioscaffolds are significant aspects that should be considered in future biomaterial optimization, which can build a foundation to ultimately achieve perfect skin regeneration outcomes.
Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
Authors: Xueping Luo, Zefeng Xu, Bing Li, Tiejun Qin, Peihong Zhang, Hongli Zhang, Liwei Fang, Lijuan Pan, Naibo Hu, Shiqiang Qu, Yue Zhang, Gang Huang, Robert Peter Gale, Zhijian Xiao
Journal: Blood Cancer Journal (2018)

Low-dose thalidomide and prednisone alone or combined are effective therapies in some persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion dependence. Danazol is also effective in some persons with PMF and anemia. Responses to these drugs are typically incomplete and not sustained. It is unclear whether adding danazol to thalidomide and prednisone would improve efficacy. We retrospectively compared the outcomes of 88 subjects with PMF and anemia receiving thalidomide and prednisone without (n = 46) or with danazol (n = 42). The primary end point was anemia response, which was 71% (95% confidence interval (CI), 57, 85%) in subjects receiving thalidomide/prednisone/danazol compared with 46% (32, 60%; P = 0.014) in those receiving thalidomide/prednisone. Response rates in subjects who were RBC transfusion dependent was also higher in the danazol cohort (61% (38, 84%)) vs. 25% (6, 44%); P = 0.024). Time to response was rapid (median, 2 months (range, 1-11 months)) and similar between the cohorts. Response duration was longer in the thalidomide/prednisone/danazol cohort (HR 2.18 (1.18-5.42); P = 0.019). Adverse effects were mild and similar between the cohorts. In conclusion, thalidomide/prednisone/danazol seems superior to thalidomide/prednisone in persons with PMF and anemia. Our conclusion requires confirmation in a randomized trial.
The African Descent and Glaucoma Evaluation Study (ADAGES) III
Authors: Linda M. Zangwill, Radha Ayyagari, Jeffrey M. Liebmann, Christopher A. Girkin, Robert Feldman, Harvey Dubiner, Keri A. Dirkes, Matthew Holmann, Eunice Williams-Steppe, Naama Hammel, Luke J. Saunders, Suzanne Vega, Kevin Sandow, Kathryn Roll, Rigby Slight, Daniel Auerbach, Brian C. Samuels, Joseph F. Panarelli, John P. Mitchell, Lama A. Al-Aswad, Sung Chul Park, Celso Tello, Jeremy Cotliar, Rajendra Bansal, Paul A. Sidoti, George A. Cioffi, Dana Blumberg, Robert Ritch, Nicholas P. Bell, Lauren S. Blieden, Garvin Davis, Felipe A. Medeiros, Maggie C.Y. Ng, Swapan K. Das, Nicholette D. Palmer, Jasmin Divers, Carl D. Langefeld, Barry I. Freedman, Donald W. Bowden, Mark A. Christopher, Yii-der I. Chen, Xiuqing Guo, Kent D. Taylor, Jerome I. Rotter, Robert N. Weinreb
Journal: Ophthalmology (2018)
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome
Authors: Eric S. Weiss, Charlotte Girard-Guyonvarc’h, Dirk Holzinger, Adriana A. de Jesus, Zeshan Tariq, Jennifer Picarsic, Eduardo J. Schiffrin, Dirk Foell, Alexei A. Grom, Sandra Ammann, Stephan Ehl, Tomoaki Hoshino, Raphaela Goldbach-Mansky, Cem Gabay, Scott W. Canna
Journal: Blood (2018)
Effects of the gut–liver axis on ischaemia-mediated hepatocellular carcinoma recurrence in the mouse liver
Authors: Lorenzo A. Orci, Stéphanie Lacotte, Vaihere Delaune, Florence Slits, Graziano Oldani, Vladimir Lazarevic, Carlo Rossetti, Laura Rubbia-Brandt, Philippe Morel, Christian Toso
Journal: Journal of Hepatology (2018)
Effects of nattokinase, profibrinolytic enzyme, on the patients with chronic rhinosinusitis with nasal polyp
Authors: Tetsuji Takabayashi, Yoshimasa Imoto, Masafumi Sakashita, Yukinori Kato, Takahiro Tokunaga, Kanako Yoshida, Norihiko Narita, Tamotsu Ishizuka, Shigeharu Fujieda
Journal: Journal of Allergy and Clinical Immunology (2018)
Participation and Dropout in the Bundled Payments for Care Improvement Initiative
Authors: Karen E. Joynt Maddox, E. John Orav, Jie Zheng, Arnold M. Epstein
Journal: JAMA (2018)

This study describes hospital participation and dropout in the Centers for Medicare & Medicaid Innovation's Bundled Payments for Care Improvement Initiative, which allows hospitals and practices to retain savings if they meet quality targets.
Identification of MEK2 and CBX7 as Top Steroid Resistant Genes in Airway ILC2s and Lymphocytes from Asthma
Authors: Kapil Sirohi, Mukesh Verma, Lidia Michalec, Anand Sripada, Donald Rollins, James Good, Richard J. Martin, Magdalena M. Gorska, Rafeul Alam
Journal: Journal of Allergy and Clinical Immunology (2018)
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i>-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial
Authors: Luca Gianni, Mauro Mansutti, Antonio Anton, Lourdes Calvo, Giancarlo Bisagni, Begoña Bermejo, Vladimir Semiglazov, Marc Thill, Jose Ignacio Chacon, Arlene Chan, Serafin Morales, Isabel Alvarez, Arrate Plazaola, Milvia Zambetti, Andrew D. Redfern, Christian Dittrich, Rebecca Alexandra Dent, Domenico Magazzù, Raffaella De Fato, Pinuccia Valagussa, Ignacio Tusquets
Journal: JAMA Oncology (2018)

Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did not reduce activity. Nab-paclitaxel is an albumin-bound nanoparticle of paclitaxel that allows for safe infusion without premedication, and its use led to a significantly higher rate of pCR in the GeparSepto trial.To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.In this multicenter, open-label study, in collaboration with Grupo Español de Investigación en Cáncer de Mama (GEICAM) and Breast Cancer Research Center-Western Australia (BCRC-WA), patients with newly diagnosed and centrally confirmed ERBB2/HER2-negative breast cancer were recruited. Participants were randomly allocated to paclitaxel, 90 mg/m2 (349 patients), or nab-paclitaxel, 125 mg/m2 (346 patients). The 2 drugs were given on weeks 1, 2, and 3 followed by 1 week of rest for 4 cycles before 4 cycles of an anthracycline regimen per investigator choice.The primary end point was the rate of pCR, defined as absence of invasive cells in the breast and axillary nodes (ie, ypT0/is ypN0) at the time of surgery. A secondary end point was to assess tolerability and safety of the 2 regimens.From May 2013 to March 2015, 814 patients were registered to the study; 695 patients met central confirmation eligibility and were randomly allocated to receive either paclitaxel (349), or nab-paclitaxel (346) (median age, 50 years; range, 25-79 years). The intention-to-treat analysis of the primary end point pCR revealed that the improved pCR rate after nab-paclitaxel (22.5%) was not statistically significant compared with paclitaxel (18.6%; odds ratio [OR], 0.77; 95% CI, 0.52-1.13; P = .19). Overall, 38 of 335 patients (11.3%) 11.3% of patients had at least 1 serious adverse event in the paclitaxel arm and 54 of 337 patient (16.0%) in the nab-paclitaxel arm. Peripheral neuropathy of grade 3 or higher occurred in 6 of 335 patients (1.8%) and in 15 of 337 (4.5%), respectively.The improved rate of pCR after nab-paclitaxel was not statistically significant. The multivariate analysis revealed that tumor subtype (triple-negative vs luminal B-like) was the most significant factor (OR, 4.85; 95% CI, 3.28-7.18) influencing treatment outcome.clinicaltrials.gov Identifier: NCT01822314.